gp iib-iiia

Tirofiban(MK383) hydrochloride monohydrate is a non-peptide glycoprotein IIb/IIIa antagonist.

Abciximab (C7E3) is a mouse human chimeric monoclonal antibody that is a potent glycoprotein IIb IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb IIIa, vitronectin and Mac-1 receptors.

GPRP acetate (Pefabloc FG) is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).

Roxifiban acetate(DMP 754 acetate) is a potent GP IIb IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.

Gantofiban is a glycoprotein IIb IIIa (GP IIb IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.

Fradafiban binds to the human platelet GP IIb IIIa complex with a Kd value of 148 nM. Fradafiban is a non-polypeptide platelet glycoprotein IIb IIIa antagonist.

SR121566A is a novel non-peptide antagonist of Glycoprotein IIb IIIa (GP IIb-IIIa).

MK 0852 is the platelet GP IIb/IIIa cyclic heptapeptide antagonist.

SK&F 107260 is an RGD-containing peptide. It is a potent GP IIb/IIIa antagonist and a vitronectin antagonist.

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Fradafiban (BIBU-52) hydrochloride is a nonpeptide antagonist of the platelet glycoprotein IIb IIIa complex, exhibiting a dissociation constant (Kd) of 148 nM for binding affinity to the human platelet GP IIb IIIa.